Burleson & Co’s Revance Therapeutics, Inc. RVNC Stock Holding History

Burleson & Co’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$5.91K	Hold	320	–	–	﹤0.01%	296
2022 Q3	$9K	Hold	320	–	–	﹤0.01%	292
2022 Q2	$4K	Hold	320	–	–	﹤0.01%	310
2022 Q1	$6K	Hold	320	–	–	﹤0.01%	298
2021 Q4	$5K	Hold	320	–	–	﹤0.01%	296
2021 Q3	$9K	Hold	320	–	–	﹤0.01%	263
2021 Q2	$9K	Hold	320	–	–	﹤0.01%	272
2021 Q1	$9K	Buy	+320	New	+$8.85K	﹤0.01%	263

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Burleson & Co's RVNC Position: Q4 2022 in Review

Burleson & Co held its Revance Therapeutics, Inc. (RVNC) position steady in Q4 2022 at 320 shares worth $5.91K. The position accounts for ﹤0.01% of the portfolio, ranked #296.

Burleson & Co first reported a position in RVNC in Q1 2021 and has held it in 8 quarters since. The position peaked at $9K in Q3 2022. 193 funds tracked by Wall St. Rank hold RVNC as of Q4 2022.

Burleson & Co held 320 shares of Revance Therapeutics, Inc. worth $5.91K as of Q4 2022.
Burleson & Co left its Revance Therapeutics, Inc. share count unchanged in Q4 2022.
Revance Therapeutics, Inc. made up ﹤0.01% of Burleson & Co's portfolio in Q4 2022, its #296 holding.
Burleson & Co first reported a position in Revance Therapeutics, Inc. in Q1 2021 and has held it in 8 quarters since.
Burleson & Co's Revance Therapeutics, Inc. position peaked at $9K in Q3 2022.
193 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2022.

Based on Burleson & Co's 13F filing for Q4 2022, filed 31 Jan 2023.